Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours

被引:68
作者
Jenkinson, Michael D. [1 ]
Smith, Trevor S.
Joyce, Kathy A.
Fildes, Diane
Broome, John
du Plessis, Daniel G.
Haylock, Brian
Husband, David J.
Warnke, Peter C.
Walker, Carol
机构
[1] Univ Liverpool, Div Neurosci, Liverpool L9 7LJ, Merseyside, England
[2] Walton Ctr Neurol & Neurosurg, Dept Neurosurg, Liverpool L9 7LJ, Merseyside, England
[3] Walton Ctr Neurol & Neurosurg, Dept Neuroradiol, Liverpool L9 7LJ, Merseyside, England
[4] Walton Ctr Neurol & Neurosurg, Dept Neuropathol, Liverpool L9 7LJ, Merseyside, England
[5] Clatterbridge Canc Res Trust, JK Douglas Labs, Wirral CH63 4JY, Merseyside, England
[6] Clatterbridge Hosp, Clatterbridge Ctr Oncol, Wirral CH63 4JY, Merseyside, England
[7] Leibniz Inst Neurobiol, Magdeburg, Germany
关键词
oligodendroglial tumour; rCBV; chemosensitivity; outcome;
D O I
10.1007/s00234-006-0122-z
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction The biological factors responsible for differential chemoresponsiveness in oligodendroglial tumours with or without the -1p/-19q genotype are unknown, but tumour vascularity may contribute. We aimed to determine whether dynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI) could distinguish molecular subtypes of oligodendroglial tumour, and examined the relationship between relative cerebral blood volume (rCBV) and outcome following procarbazine, lomustine and vincristine (PCV) chemotherapy. Methods Pretherapy rCBV was calculated and inter- and intraobserver variability assessed. Allelic imbalance in 1p36, 19q13, 17p13, 10p12-15, and 10q22-26 and p53 mutation (exons 5-8) were determined. rCBV was compared with genotype and clinicopathological characteristics (n=37) and outcome following PCV chemotherapy (n=33). Results 1p/19q loss was seen in 6/9 grade II oligodendrogliomas, 6/14 grade II oligoastrocytomas, 4/4 grade III oligodendrogliomas, and 3/10 grade III oligoastrocytomas. rCBV measurements had good inter- and intraobserver variability, but did not distinguish histology subtype or grade. Tumours with 1p/19q loss had higher rCBV values (Student's t-test P=0.001). Receiver operating characteristic analysis revealed a cut-off of 1.59 for identifying genotype (sensitivity 92%, specificity 76%). Tumours with high and low rCBV showed response to chemotherapy. The -1p/-19q genotype, but not rCBV, was strongly associated with response, progression-free and overall survival following PCV chemotherapy. Tumours with high rCBV and intact 1p/19q were associated with shorter progression-free and overall patient survival than those with intact 1p/19q and low rCBV or high rCBV and 1p/19q loss. Conclusion rCBV identifies oligodendroglial tumours with 1p/19q loss, but does not predict chemosensitivity. The prognostic significance of rCBV may differ in oligodendroglial tumours with or without the -1p/-19q genotype.
引用
收藏
页码:703 / 713
页数:11
相关论文
共 37 条
[1]  
[Anonymous], 2000, World Health Organisation Classification of Tumours: Pathology and genetics of tumours of the nervous system
[2]   CEREBRAL BLOOD-VOLUME MAPS OF GLIOMAS - COMPARISON WITH TUMOR GRADE AND HISTOLOGIC-FINDINGS [J].
ARONEN, HJ ;
GAZIT, IE ;
LOUIS, DN ;
BUCHBINDER, BR ;
PARDO, FS ;
WEISSKOFF, RM ;
HARSH, GR ;
COSGROVE, GR ;
HALPERN, EF ;
HOCHBERG, FH ;
ROSEN, BR .
RADIOLOGY, 1994, 191 (01) :41-51
[3]  
Aronen HJ, 2000, CLIN CANCER RES, V6, P2189
[4]  
Birner P, 2001, CANCER, V92, P165, DOI 10.1002/1097-0142(20010701)92:1<165::AID-CNCR1305>3.0.CO
[5]  
2-F
[6]   STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT [J].
BLAND, JM ;
ALTMAN, DG .
LANCET, 1986, 1 (8476) :307-310
[7]   Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: Efficacy and associations with chromosomal abnormalities [J].
Buckner, JC ;
Gesme, D ;
O'Fallon, JR ;
Hammock, JE ;
Stafford, S ;
Brown, PD ;
Hawkins, R ;
Scheithauer, BW ;
Erickson, BJ ;
Levitt, R ;
Shaw, EG ;
Jenkins, R .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :251-255
[8]   Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas [J].
Cairncross, JG ;
Ueki, K ;
Zlatescu, MC ;
Lisle, DK ;
Finkelstein, DM ;
Hammond, RR ;
Silver, JS ;
Stark, PC ;
Macdonald, DR ;
Ino, Y ;
Ramsay, DA ;
Louis, DN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) :1473-1479
[9]  
Cha S, 2005, AM J NEURORADIOL, V26, P266
[10]   Intracranial mass lesions: Dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging [J].
Cha, S ;
Knopp, EA ;
Johnson, G ;
Wetzel, SG ;
Litt, AW ;
Zagzag, D .
RADIOLOGY, 2002, 223 (01) :11-29